A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in participants with Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have Prog

The purpose of this study is to test the safety of the study drug, pembrolizumab, in combination with a chemotherapy plus a steroid on participants with mCRPC with disease progression after being treated with a NHA. The study will determine the safety and efficacy of pembrolizumab compared to placebo (a look-alike with no active ingredients) in combination with a chemotherapy and a steroid. Pembrolizumab (MK-3475), also known as KEYTRUDA®.

For more information go to https://clinicaltrials.gov/ct2/show/NCT03834506

Inova Schar Cancer Institute
A department of Inova Fairfax Hospital
8081 Innovation Park Blvd.
Fairfax, VA 22031

• Male participants with mCRPC in the pre-chemotherapy stage of treatment
• Current evidence of metastatic disease
• Additional eligibility in protocol

• Active autoimmune disease
• Gastrointestinal disorders affecting absorption
• Active central nervous system metastases
• Additional ineligibility in protocol